Hepatology News

President Biden’s administration has had a sharp focus on competition issues in health care mergers and acquisitions.

Subcutaneous pegozafermin at weekly and biweekly doses improved fibrosis at 24 weeks vs. placebo among patients with biopsy-confirmed nonalcoholic steatohepatitis, supporting the therapy’s advancement to phase 3 development, data showed.

Dietary supplementation with resistant starch reduced intrahepatic triglyceride content and may help manage disease by altering gut microbiota among patients with nonalcoholic fatty liver disease, according to data in Cell Metabolism.

Liver disease was the primary cause of death in patients with alcohol-related liver disease several years after diagnosis, with the risk for mortality almost three times higher in those with decompensated cirrhosis, according to research.

An automated best practice advisory within the electronic health record can improve infectious disease screening in patients with autoimmune and rheumatic conditions, according to data published in Arthritis Care & Research.

A surge of blockbuster anti-obesity drugs has dramatically changed the landscape for chronic weight management and opened new avenues of research in gastrointestinal and liver disease alongside concerns for potential GI side effects.

Although fibrosis-4 index and NAFLD fibrosis score did not significantly differ in diagnosing advanced fibrosis in nonalcoholic fatty liver disease, fibrosis-4 may be a better screening tool in lean patients, according to a study.

Mergers and acquisitions have come to private practice medicine during the last 5 years — and in a big way. It would be difficult to find a physician of any specialty in any U.S. location who is not aware of this trend.

Rates of hepatocellular carcinoma caused by alcohol-related disease and nonalcoholic fatty liver disease are on the rise, especially among Hispanic individuals, according to research in Clinical Gastroenterology and Hepatology.

International Primary Biliary Cholangitis Day, celebrated on September 10, aspires to raise awareness of the challenges that patients with this rare liver disease face and how their stories can help advance diagnosis, treatment and care.